ADMA
ADMA Biologics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.21B
P/E Ratio
15.47
EPS
$0.60
Beta
0.82
52W High
$25.67
52W Low
$7.21
50-Day MA
$14.96
200-Day MA
$16.60
Dividend Yield
—
Profit Margin
28.80%
Forward P/E
28.99
PEG Ratio
0.00
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
Fundamentals
| Revenue (TTM) | $510.17M |
| Gross Profit (TTM) | $292.76M |
| EBITDA | $199.54M |
| Operating Margin | -123.40% |
| Return on Equity | 35.60% |
| Return on Assets | 21.50% |
| Revenue/Share (TTM) | $2.14 |
| Book Value | $2.01 |
| Price-to-Book | 4.58 |
| Price-to-Sales (TTM) | 4.33 |
| EV/Revenue | 4.275 |
| EV/EBITDA | 11.02 |
| Quarterly Earnings Growth (YoY) | -52.80% |
| Quarterly Revenue Growth (YoY) | 15.90% |
| Shares Outstanding | $238.16M |
| Float | $233.17M |
| % Insiders | 2.64% |
| % Institutions | 94.86% |
Analyst Ratings
Consensus ($23.50 target)
3
BuyData last updated: 4/7/2026